CEDRUS INVESTMENTS HOSTED LIFE SCIENCES LUNCHEON IN SHANGHAI, 13TH NOVEMBER 2017

SHANGHAI, 14th November 2017 – Cedrus Investments (“Cedrus”), a global boutique
investment firm, hosted the second meeting of the life sciences luncheon series for this year on Monday, 13th November 2017 in Shanghai at the St. Regis Shanghai Jingan. Mr. Randy Hice, Cedrus’ Chief Technical Officer and Member of the Life Sciences Advisory Board, shared with institutional investors, venture capitalists, and company executives his insights on two crucial themes in biotechnology: “New Frontiers in Immunology R&D” and “Increasing Laboratory Productivity and Meeting FDA Compliance through Software”.
Mr. Hice is recognized globally as a leading authority in laboratory informatics and the most published author in the world on topics of complex laboratory automation and workflow analysis. His recent positions included the CEO of Laboratory Expertise Center, Inc. and Manager of Global Strategy at Abbott Informatics, a division of Abbott Laboratories.

 

The event was well received, and elicited high-level discussion in the Q&A session following Mr. Hice’s speech. Investors thought that it was especially important to understand the very latest developments in the biotech industry, as well as the overseas regulatory environment in order to conform to international conventions. Those attended the luncheon included executives from Fountainvest Partners, Franklin Templeton Sealand, Qiming VC, and SAIF Partners.
Cedrus’ Chief Technical Officer, Mr. Randy Hice said, “I am glad to be able to share the
latest trends in immunology research and development with investors and companies, as well as providing some perspectives on how progressive scientific enterprises are utilizing the latest tools available to improve their data quality while achieving FDA compliance. The feedback from the event’s participants provided us with a better understanding of the active areas of interest from Chinese life sciences investors and companies, and that understanding will no doubt facilitate future cooperation regarding cross-border transactions and investment opportunities.”
Cedrus’ Chairman, Mr. Rani Jarkas said, “With its particular focus on the Greater China region, Cedrus has always positioned itself as a leader in fulfilling the needs of the investment community and companies around the world. Given our global network and expertise in the life sciences industry, we can serve as the platform for both investors and companies worldwide, facilitating both inbound and outbound investments for the Chinese and other geographical markets.”

 

#RaniJarkas, #CedrusInvestments

 

Advertisements

中国精准医疗的未来

precision

自美国总统奥巴马2015年初宣布启动新的医疗研究努力——精准医疗计划以来,中国也在指定自己更大的精准医疗项目。中国一些领先研究机构包括清华大学复旦大学以及中国医学科学院都纷纷建立精准医学中心。例如四川大学华西医院计划完成一百万个人体基因序列,与整个美国的计划目标相同。

中国政府有望在今年3月份批准下一个五年计划,尽管目前还不清楚将会投入多少资金,但几乎可以肯定的是, 会比美国2.15亿美元的计划规模更大,投入的资金更多。

今年1月9日,中国科学院宣布启动“中国人群精准医学研究计划”,将在4年内完成4,000名志愿者的基因信息采集。

当前中国一些基因测序公司已相继竞争提供测序服务,中国多年以来为超高的基因测序能力而引以为傲。2010年,总部位于深圳的基因研究院华大基因估测其测序能力超过了整个美国。但这也要感谢其从加州圣迭戈Illumina公司购买的设备,这些设备在当时代表着最为尖端的技术。但中国的其他基因公司随后也从Illumina公司购买了升级后的产品,包括来自上海的药明康德云健康基因,以及来自北京的诺禾致源

美国国立卫生研究院院长弗朗西斯•柯林斯于2015年大连夏季达沃斯论坛上表示,他希望在未来看到中美双方在精准医疗上更多的合作。

我认为,中国在基因序列和识别突变基因这些与个性化治疗相关的方面发展会比美国迅速,这是因为中国每种疾病都有庞大的病患数量,使得研究拥有足够的样本,加之中国政府对成功的决心。然而,中国能否将这些发现都应用到患者的个性化治疗上面,仍然有待观察。

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas